Get the Stockscreener App
4.66
0.43%
0.02
After Hours:
4.70
0.04
+0.86%
Personalis Inc stock is traded at $4.66, with a volume of 479.39K.
It is up +0.43% in the last 24 hours and down -24.84% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$4.64
Open:
$4.64
24h Volume:
479.39K
Relative Volume:
0.41
Market Cap:
$413.24M
Revenue:
$73.48M
Net Income/Loss:
$-108.30M
P/E Ratio:
-2.0711
EPS:
-2.25
Net Cash Flow:
$-67.17M
1W Performance:
+0.00%
1M Performance:
-24.84%
6M Performance:
-1.17%
1Y Performance:
-26.50%
1-Day Range:
$4.59
$4.69
1-Week Range:
$4.44
$4.88
52-Week Range:
$2.8262
$7.79
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
4.66 | 430.08M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
483.76 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
203.90 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
633.05 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
117.15 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
185.39 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Watch for Bullish Crossover in Personalis Inc.2025 Breakouts & Breakdowns & Accurate Entry and Exit Point Alerts - beatles.ru
Personalis, Inc. (NASDAQ:PSNL) Q2 2025 Earnings Call Transcript - MSN
Live market analysis of Personalis Inc.July 2025 Chart Watch & Free High Return Stock Watch Alerts - Newser
Personalis Inc. May Be Forming Higher Low — Chartwatchers AlertPortfolio Risk Report & Growth Oriented Trading Recommendations - 선데이타임즈
Reversal indicators forming on Personalis Inc. stockWeekly Profit Recap & Stock Market Timing Techniques - Newser
Sector Leaders Rotate Capital Into Personalis Inc.Weekly Trading Summary & Breakout Confirmation Alerts - sundaytimes.kr
What makes Personalis Inc. stock price move sharplyJuly 2025 Price Swings & Verified Momentum Stock Watchlist - Newser
Is now a turning point for Personalis Inc.2025 Price Targets & Expert Curated Trade Setup Alerts - Newser
Statistical indicators supporting Personalis Inc.’s strengthWeekly Earnings Recap & AI Driven Stock Price Forecasts - Newser
Will Personalis Inc. stock go up soonRate Hike & Safe Swing Trade Setups - Newser
News impact scoring models applied to Personalis Inc.Quarterly Trade Review & Reliable Breakout Forecasts - Newser
Tick level data insight on Personalis Inc. volatility2025 Support & Resistance & Technical Confirmation Trade Alerts - Newser
Is PSNL's 28% Drop a Buying Opportunity or a Warning Sign? A Deep Dive into Personalis' Financials and Future - AInvest
Developing predictive dashboards with Personalis Inc. dataJuly 2025 Institutional & Fast Entry and Exit Trade Plans - Newser
Why Personalis Inc. stock attracts strong analyst attentionMarket Movement Recap & Pattern Based Trade Signal System - Newser
Will earnings trigger a reversal in Personalis Inc.July 2025 Rallies & Real-Time Market Trend Scan - Newser
Why Personalis Inc. is moving today2025 Dividend Review & Weekly Top Performers Watchlists - Newser
Measuring Personalis Inc.’s beta against major indicesJuly 2025 EndofMonth & Fast Momentum Entry Tips - Newser
Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL) - Yahoo Finance
Personalis Inc. Crosses 200 Day MA — Signal or NoiseFast Return Equity Trade Forecast Points to Small Caps - 선데이타임즈
Does Personalis Inc. have declining or rising EPSMassive Potential Swing Trades - thegnnews.com
After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL) - Yahoo Finance
Craig-Hallum Analyst Maintains Buy Rating on Personalis with $7 Price Target - AInvest
Personalis (NASDAQ:PSNL) Cut to Sell at Wall Street Zen - Defense World
Personalis, Inc. (NASDAQ:PSNL) Stake Boosted by XTX Topco Ltd - Defense World
Long term hold vs stop loss in Personalis Inc.Technical Confirmation System with Signal Alerts - Newser
These Analysts Think Personalis, Inc.'s (NASDAQ:PSNL) Sales Are Under Threat - simplywall.st
What recovery options are there for Personalis Inc.Free High Return Stock Focus With Safety - Newser
What is HC Wainwright’s Forecast for Personalis Q3 Earnings? - Defense World
Personalis outlines $70M–$80M revenue target for 2025 amid 59% sequential clinical test growth and revised biopharma outlook - MSN
All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy - Yahoo Finance
Lake Street Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $9 - 富途牛牛
Personalis, Inc. (NASDAQ:PSNL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - uk.finance.yahoo.com
HC Wainwright & Co. Maintains Buy Rating on Personalis, Lowers Price Target to $8.50 - AInvest
Personalis, Inc. shares fall 1.03% after-hours following a securities lawsuit against Tempus AI, Inc. - AInvest
A Quick Look at Today's Ratings for Personalis(PSNL.US), With a Forecast Between $6 to $9 - 富途牛牛
Personalis Inc (PSNL) Getting Ready To Launch, Waiting For The Long Term Buyers - stocksregister.com
Personalis Reports Q2 2025 Financial Results - The Globe and Mail
Personalis Earnings Call: Growth Amidst Financial Challenges - TipRanks
Personalis (PSNL) Q2 Revenue Falls 24% - AOL.com
Personalis reports Q2 EPS (23c), consensus (24c) - MSN
Personalis Plunges 22.87% Amid Sector-Wide Turmoil: What Triggers This Freefall and How to Position? - AInvest
PSNL: HC Wainwright & Co. Lowers Target Price, Maintains Buy Rat - GuruFocus
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - 富途牛牛
Personalis 2025 Q2 Earnings Sustained Losses Despite Sequential Clinical Growth - AInvest
Personalis: Strong Molecular Testing Growth and Strategic MRD Focus Support Buy Rating - TipRanks
Personalis Plunges 26.06% on Revenue Targets - AInvest
Personalis: Q2 Earnings Snapshot - Huron Daily Tribune
Personalis (PSNL) Q2 Revenue Falls 24% - The Motley Fool
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Personalis Inc Stock (PSNL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tachibana Aaron | CFO AND COO |
Jul 28 '25 |
Sale |
6.57 |
641 |
4,211 |
164,458 |
| Tachibana Aaron | CFO AND COO |
May 16 '25 |
Sale |
4.95 |
1,291 |
6,390 |
165,099 |
| Moore Stephen Michael | SVP and Chief Legal Officer |
May 16 '25 |
Sale |
4.95 |
1,675 |
8,291 |
64,200 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
May 16 '25 |
Sale |
4.95 |
910 |
4,504 |
124,957 |
| Tachibana Aaron | CFO AND COO |
Jan 28 '25 |
Sale |
5.79 |
708 |
4,099 |
166,390 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Jan 28 '25 |
Sale |
5.79 |
519 |
3,005 |
123,367 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Dec 16 '24 |
Sale |
3.82 |
4,834 |
18,466 |
123,886 |
| Moore Stephen Michael | SVP and Chief Legal Officer |
Dec 16 '24 |
Sale |
3.82 |
1,513 |
5,780 |
65,875 |
| Tachibana Aaron | CFO AND COO |
Dec 16 '24 |
Sale |
3.82 |
6,865 |
26,224 |
167,098 |
| Tachibana Aaron | CFO AND COO |
Nov 18 '24 |
Sale |
3.79 |
1,307 |
4,954 |
173,963 |
2.12%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):